Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2006

View Archived Issues

RhuDex preclinical activity, human pharmacokinetics reported

Neramexane potentiates the efficacy of antidepressants

Benefits of add-on niacin therapy demonstrated in hypercholesterolemia

Activity of RAD-001 and depot octreotide explored in neuroendocrine tumors

Preliminary phase II results show activity of ZD-6474 in medullary thyroid carcinoma

Rigel present a new class of antimitotic agents for cancer therapy

F-15845: a new agent for cardiac ischemia

MediGene and German Cancer Research Center cooperate in ovarian cancer

Statement from TeGenero: Insolvency proceedings were initiated

EMEA validates Iplex submission

Aradigm and Novo Nordisk restructure agreement

Salix files for pediatric exclusivity of Colazal

Promising in vivo results of Pluristem's adjuvant cell therapy product PLX-1

Baxter studies Vero-cell based H5N1 pandemic influenza vaccine in phase I/II trial

Abbott and AstraZeneca to develop fibrate and statin combination treatment

First collaborative compound from Actelion and Merck renin alliance enters clinic

Johnson & Johnson to acquire Pfizer Consumer Healthcare

ISIS-301012 q.o.w. reduces LDL-C and apoB in subjects with mild hypercholesterolemia

Recent patents report new treatment strategies for respiratory diseases

Recent patents describe new therapeutic agents for depression, anxiety, etc.

NDA filing for T-Pred in inflammatory ocular conditions

Valera files for approval of Supprelin-LA in central precocious puberty

Tentative approval for generic three-in-one antiretroviral product

IL-1 Trap demonstrates preliminary efficacy in systemic juvenile idiopathic arthritis

New results of phase I/II studies on tgAAC94 from Targeted Genetics

Further data on IC-31's ability to increase efficacy of TB vaccine Ag85B-ESAT-6

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...